FNP-223 is an experimental oral medication being studied for its potential to slow down the progression of Progressive Supranuclear Palsy (PSP), a rare brain disorder. This medication is being tested to see if it can help patients with PSP maintain their physical abilities and daily functions for a longer time. The medication is taken by mouth and is being evaluated for both its effectiveness and safety in treating PSP symptoms.

Progressive Supranuclear Palsy (PSP) – A rare brain disorder that causes serious problems with walking, balance, eye movements, and swallowing. The condition gradually damages specific areas of the brain above nerve cell clusters called nuclei that control eye movements. People with PSP develop difficulties with balance and walking, which worsen over time. The disease also causes problems with eye movement, particularly with looking up and down, along with speech difficulties and trouble swallowing. Additionally, people may experience changes in mood and behavior, as well as mild thinking problems. The condition typically develops in people over the age of 60, though it can occur earlier.